ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
16 Nov 2025 10:10

HK Short Interest Weekly: AIA, Wuxi Apptec, HSCEI ETF

We analyzed the latest HK SFC report for aggregate short position as of Nov 7th and highlight short interest changes in AIA, Wuxi Apptec, HSCEI ETF.

Logo
301 Views
Share
16 Nov 2025 10:05

HK Connect Flows Weekly (Nov 14th): Alibaba, Xiaomi, CNOOC, ICBC, Ping An Insurance, Petrochina

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Xiaomi, CNOOC, ICBC, Ping An Insurance, Petrochina.

Logo
558 Views
Share
14 Nov 2025 10:41

Hong Kong Buybacks Weekly (Nov 14th): China Feihe, Cosco Shipping, Sinopec

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were China Feihe (6186...

Logo
257 Views
Share
07 Nov 2025 11:29

Hong Kong Buybacks Weekly (Nov 7th): Cosco Shipping, China Feihe, Sinopec

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Cosco Shipping...

Logo
217 Views
Share
03 Nov 2025 11:30

Hong Kong Connect Flows (October): $792m Outflows from Healthcare

We estimated the inflows to Hong Kong stocks from mainland investors to be USD 11bn in October and noted outflows of $792m from Healthcare sector.

Logo
437 Views
Share
x